Landscape phage ligands for PC3 prostate carcinoma cells.
Tumor-specific cytotoxicity of drugs can be enhanced by targeting them to tumor receptors using tumor-specific ligands. Phage display technology with its high throughput capacity for the analysis of targeting ligands possessing specific binding properties represents a very attractive tool in the quest for molecular ligands. Also, current phage nanobiotechnology concepts allow the use of intact phage particles and isolated phage coat proteins per se as components of nanomedicines. Herein, we describe the use of two landscape phage libraries to obtain phage ligands against PC3 prostate carcinoma cells. Following a very stringent selection scheme, we were able to identify three phage ligands, bearing the fusion peptides, DTDSHVNL, DTPYDLTG and DVVYALSDD that demonstrated specificity and selectivity to PC3 cells based on target-association assays, microscopy and flow cytometry. The phage ligands and their fusion coat proteins can be used as navigating modules in both therapeutic and diagnostic approaches to prostate carcinoma.
Jayanna
P K
PK
Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, AL 36849, USA.
Bedi
D
D
Deinnocentes
P
P
Bird
R C
RC
Petrenko
V A
VA
D000704:Analysis of Variance; D045744:Cell Line, Tumor; D004926:Escherichia coli; D005434:Flow Cytometry; D006801:Humans; D008024:Ligands; D008297:Male; D009842:Oligopeptides / Q000737:chemistry / Q000378:metabolism*; D019151:Peptide Library; D011471:Prostatic Neoplasms / Q000378:metabolism*; D011993:Recombinant Fusion Proteins / Q000737:chemistry / Q000378:metabolism*; D012680:Sensitivity and Specificity
D008024:Ligands; D009842:Oligopeptides; D019151:Peptide Library; D011993:Recombinant Fusion Proteins